The Chinese company will use the funds to accelerate the registration and commercialization of its NGS-based products for cancer screening and early detection.
The company had been working to expand its retrospective data over the last year and half and is now readying to move forward with prospective studies.
The company aims to use the methylation technology from its multi-cancer screening assay to detect minimal residual disease in early-stage cancer patients.
The Universities of Southampton and Leeds will lead the project with participation from Johnson & Johnson, Roche, Oncimmune, BC Platforms, Inivata, and NHS England.
The company believes its tests can already help oncologists better assess post-surgery risk, though prospective validation would be necessary for broad claims.
